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Background
The development of safe and effective topical microbi-
cides to limit the continuing AIDS pandemic is a high pri-
ority. The current NIAID microbicide testing algorithm
includes both CCR5 (R5)-tropic and CXCR4 (X4)-tropic
attachment inhibition assays, and an X4-tropic fusion
inhibition assay. To complete this testing algorithm, an
R5-tropic fusion inhibition assay was developed. The
rationale for this development was that mucosal HIV-1
infection is primarily mediated through the R5 receptor
and an R5-tropic entry inhibitor should be included in
combination microbicide prophylaxis.
Materials and methods
The assay employs ADA/ENV cells (an HIV-1 ADA enve-
lope and Tat expressing HeLa cell line) as the effector cells
and MAGI-R5 (HeLa cells expressing CD4, R5, and an
HIV-1 LTR driven β-galactosidase reporter) as the target
cells. Upon co-culture of the two cell lines, HIV-1 enve-
lope mediated cell-to-cell fusion occurs resulting in trans-
activation of the β-galactosidase reporter gene.
Results and Conclusion
Varying effector-to-target cell ratios were evaluated and a
ratio of 1:2 was found to be optimal for the assay (i.e., 5 ×
103 effector and 104 target cells). The R5 inhibitors SCH-
D, SCH-C, Maraviroc, and TAK-779 were highly active in
the assay, with 50% inhibitory concentrations ranging
from 1 to 40 nM. A proprietary fusion peptide, based on
the C34 peptide, was also active. As expected, the X4
inhibitor AMD3100, Dextran, and all tested NRTIs,
NNRTIs, and protease inhibitors were inactive in the
assay. In order to determine suitability for high through-
put screening, the robustness of the assay was assessed by
determining the Z'-value in a 96-well plate format, yield-
ing a Z'-value of 0.7. Assay validation in the 384-well plate
format is in progress. (This work was funded by contract
N01-AI-05415; Dr. Roger Miller, Project Officer.)
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